HNSA
Hansa Biopharma AB
FDA PDUFA Target Action Date
Saturday, December 19, 2026
265 days away
Drug Information
- Drug Name
- Imlifidase
- Indication
- Kidney transplant desensitization (highly sensitized patients)
Filing Details
- Company
- Hansa Biopharma AB
- Stock Ticker
- HNSA
- SEC CIK
- Source
- PRNewswire →
What is a PDUFA Date?
A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.
- Standard Review: 10 months from filing acceptance
- Priority Review: 6 months from filing acceptance
- Possible Outcomes: Approval, Complete Response Letter (CRL), or extension
Track All FDA Decisions
View all upcoming PDUFA dates and AdCom meetings on our FDA Calendar.
View FDA Calendar →Data sourced from SEC EDGAR filings. Last updated: 2026-03-22. Report an issue